Technology
Applications and enabling opportunities
The RheaVita Continuous Freeze-Drying Technology is compatible with all kinds of containers, like vials or dual chamber cartridges, as long as they are cylindrical. All kinds of products can be processed using the RheaVita Technology: proteins, viruses, bacteria, mRNA LNPs, ATMPs and other biopharmaceuticals.
Benefits
Conventional pharmaceutical batch freeze-drying is inherently associated with several The RheaVita Continuous Freeze-Drying Technology brings important value to the pharmaceutical industry. The RheaVita Continuous Freeze-Drying Technology brings the following value to the pharmaceutical industry:
- Time & Financial savings
- Improved quality
- Improved flexibility
Concept
The RheaVita Continuous Freeze-Drying Technology is based on spinning the vials while cooling and freezing making use of cold gas, resulting in a thin product layer spread over the inner vial wall. The spin frozen vials are subsequently dried under vacuum, where individual infrared heaters provide the radiative energy transfer for ice sublimation.
PAT
Process Analytical Technologies (PAT) for process monitoring and control of critical process and product parameters at the level of each individual vial (100% inspection) are an essential part of the RheaVita continuous freeze-drying technology. Several process analytical tools (PAT), such as near-infrared spectroscopy (NIR) spectroscopy and thermal imaging are built in.
Intellectual property
The unique RheaVita Continuous Freeze-Drying Technology is the result from an extensive model-based R&D approach. The concept and its related features are all protected by international PCT patents.
